Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.56 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5574084 | 1.00 | GRM8 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL29595857 | 0.88 | ENPEP (0.46) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL28528076 | 0.85 | BLM (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL5574087 | 0.85 | BLM (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL22388932 | 0.82 | GRM8 (0.54) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL28255308 | 0.80 | SLC15A1 (0.62) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL29814175 | 0.79 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL19088203 | 0.79 | DPP4 (0.51) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL709483 | 0.78 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL709482 | 0.78 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0708660-A1 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-01 | — | — | EP | claimed |
| WO-1995002420-A2 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD. (GB) | 1995-01-26 | — | — | WO | claimed |
| US-12508271-B2 | Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4637843-A2 | METHODS AND MATERIALS FOR COMBINING BIOLOGICS WITH MULTIPLE CHELATORS | Mayo Foundation for Medical Education and Research (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025101390-A1 | USE OF ACRYLIC ACID-CONTAINING POLYMERS FOR MOLECULAR IMAGING OF TARGET PROTEINS | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-113453720-B | Dual ligand drug conjugate and uses thereof | 同宜医药（苏州）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-3609544-B1 | PRODRUGS OF 2-PMPA FOR HEALTHY TISSUE PROTECTION DURING PSMA-TARGETED CANCER IMAGING OR RADIOTHERAPY | UNIV JOHNS HOPKINS (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025042989-A1 | PSMA-BASED ALBUMIN BINDING AGENTS FOR TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-4511379-A2 | THERANOSTIC SILICON-FLUORIDE HETEROAROMATIC SYSTEMS AND METHODS THEREOF | Fuzionaire Theranostics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119301134-A | Silicon fluoride heteroaromatic systems for theranostics and methods therefor | 富齐奥奈尔治疗诊断股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4046996-A1 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | Universität Bielefeld (DE) | 2022-08-24 | — | — | EP | disclosed |
| US-20220194904-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | CORNELL UNIVERSITY (US) | 2022-06-23 | — | — | US | disclosed |
| EP-4008359-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-3723815-B1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | UNIV MUENCHEN TECH (DE) | 2022-04-20 | — | — | EP | disclosed |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| EP-0711177-B1 | IMPROVEMENTS RELATING TO THE PREPARATION OF PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2007-05-09 | — | — | EP | disclosed |
| EP-0708660-B1 | COMPOUNDS USEFUL FOR PREPARING PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RES CAMPAIGN TECH (GB) | 2007-05-09 | — | — | EP | disclosed |
| US-5770731-A | PROTECTING GROUPS, ANTIBODY DIRECTED ENZYME/PRODRUG THERAPY, ANTICARCINOGENIC AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| US-5728868-A | Prodrugs of protein tyrosine kinase inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | PBRM1, BRWD1, BRDT | GRM8 1109/4885GRM6 592/4885GRIN2D 2981/4885 |
| US-12508271-B2 | Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy | KLK3, CTSA, PTMA | GRM8 3864/4885GRM6 3710/4885GRIN2D 3534/4885 |
| US-20220194904-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | PSMA3, FOLH1, PSMA1 | GRM8 3064/4885GRM6 3645/4885GRIN2D 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.